3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Colorectal Neoplasms
13
Neoplasms
11
Neoplasm Metastasis
11
Rectal Neoplasms
6
Lymphoma, Non-Hodgkin
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Ovarian Neoplasms
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Lymphoma, B-Cell, Marginal Zone
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Fallopian Tube Neoplasms
4
Colorectal Cancer Metastatic
4
Colonic Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Burkitt Lymphoma
4
Urinary Bladder Neoplasms
3
Urethral Neoplasms
3
Prostatic Neoplasms
3
Endometrial Neoplasms
3
Vulvar Neoplasms
2
Vaginal Neoplasms
2
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Testicular Neoplasms
2
Stomach Neoplasms
2
Sarcoma
2
Penile Neoplasms
2
Interventions
Gemcitabine
35
Cisplatin
21
Capecitabine
17
Oxaliplatin
16
Leucovorin
11
Fluorouracil
11
pembrolizumab
8
S 1 (combination)
8
Nivolumab
6
tremelimumab
5
durvalumab
5
Bevacizumab
5
lenvatinib
4
Irinotecan
4
trametinib
3
titanium silicide
3
atezolizumab
3
Radiofrequency Ablation
3
zanidatamab
2
vandetanib
2
irinotecan sucrosofate
2
derazantinib
2
camrelizumab
2
binimetinib
2
apatinib
2
Trastuzumab
2
Tegafur
2
Radiotherapy
2
Panitumumab
2
Ipilimumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Biliary Tract Neoplasms
×
aflibercept
×
Clear all
NCT01843725
2018-01-31
MOMENTUM1
Jules Bordet Institute
Phase 1
Completed
37 enrolled